Biomarin Pharmaceutical (BMRN) EBITDA (2009 - 2026)

Biomarin Pharmaceutical has disclosed EBITDA across 18 years of filings, most recently posting $114.8 million for Q1 2026.

• Quarterly EBITDA fell 19.85% year-over-year to $114.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $226.9 million (down 56.67% YoY) and the FY2025 annual result came in at $409.5 million, down 15.43% from the prior year.
• EBITDA advanced to $114.8 million in Q1 2026, from -$44.6 million in the prior quarter.
• Over five years, EBITDA peaked at $176.8 million in Q2 2025 and troughed at -$44.6 million in Q4 2025.
• A 5-year average of $70.4 million and a median of $65.3 million in 2023 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA soared 1060.04% — and 2025, when it slumped 127.64%.
• Tracing BMRN's EBITDA over 5 years: stood at -$13.1 million in 2022, then jumped by 308.43% to $27.3 million in 2023, then jumped by 491.69% to $161.4 million in 2024, then slumped by 127.64% to -$44.6 million in 2025, then jumped by 357.26% to $114.8 million in 2026.
• Business Quant data shows BMRN's EBITDA at $114.8 million in Q1 2026, -$44.6 million in Q4 2025, and -$20.1 million in Q3 2025.